Overview

Double Blind Comparative Study of TAK-875

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Glimepiride
Criteria
Inclusion Criteria:

- The participant is an outpatient.

- The participant signs and dates a written, informed consent form and any required
privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

- The participant has any serious cardiac disease, serious cerebrovascular disorder, or
any serious pancreatic or hematological disease.

- The participant is considered ineligible for the study for any other reason by the
investigator or subinvestigator.